Exai Bio Analysis
What is Exai Bio?
RNA & AI liquid biopsy for early cancer detection from blood samples
Location
Palo Alto, United States
Employees
11-50
Founded
2021
Product Features & Capabilities
- Proprietary oncRNA biomarkers
- AI-powered cancer signal detection
- Early cancer diagnosis from blood samples
- Clinical insights into cancer biology
Use Cases
Detect cancer in pre-symptomatic patients; Identify cancer signals in blood samples with high sensitivity; Provide clinical insights into tumor biology; Enable early intervention before symptoms appear; Diagnose cancer with accuracy surpassing traditional methods
Other Considerations
Founded with technology from UCSF's Dr. Hani Goodarzi lab; Veteran leaders in RNA biology and AI/ML from academia and industry; Backed by Section 32, Casdin Capital, and Two Sigma Ventures; HQ in Palo Alto, CA
See something that needs updating? Suggest edits to this profile.